Alternative dry eye disease treatment effective

Article

Sodium hyaluronate (SH) and carboxymethylcellulose (CMC) are safe and effective in treating mild to moderate dry eye disease

Sodium hyaluronate (SH) and carboxymethylcellulose (CMC) are safe and effective in treating mild to moderate dry eye disease, claimed an investigation published in Cornea.

Dr Ji Hwan Lee and his team at The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea, saw a significant improvement in both SH and CMC groups after treatment.

The prospective, randomized, blind study focused on 67 mild to moderate dry eye patients. There were 32 patients in the SH group and 33 patients in the CMC group. For 8 weeks they were administered preservative-free unit dose formula eyedrops of 0.1% SH or 0.5% CMC 6 times a day. The outcome measures included tear film break-up time, adverse reactions, subjective symptoms and corneal and conjunctival staining with fluorescein. The patients were assessed 4 weeks and 8 weeks after treatment began.

Tear film break-up time, dry eye symptom score and corneal and conjunctival staining significantly improved. There was no significant difference between both groups and no adverse reactions in the follow-up period.

SH and CMC were found to be efficient in the treatment of mild to moderate dry eye disease in the form of a preservative-free artificial tear formulation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.